In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
Dr. Casey Means, nominated by Trump for Surgeon General, faces a tough Senate hearing amid controversy over her qualifications and views on vaccines and health. Can she convince lawmakers she's fit for the role?
Health Secretary Robert F. Kennedy, Jr. makes controversial claims linking Tylenol to autism, igniting debate over his unproven theories and their implications for public health policies.
In a chaotic meeting, RFK Jr.'s vaccine panel voted against requiring prescriptions for Covid-19 shots. Confusion reigned as panelists struggled with their roles, raising questions about vaccine safety and governance.
The CDC has adopted new guidelines for COVID-19 vaccines that require patients to consult healthcare providers before vaccination, sparking confusion and concern about access and safety.
Parents like Remy Sweeney-Garrett are frustrated as CDC delays hinder COVID-19 vaccinations for children. With winter approaching, the lack of guidance raises fears about health risks, especially for vulnerable kids.
The FDA's approval of a new generic version of mifepristone has sparked backlash from anti-abortion groups and GOP politicians. Critics say it's a political move during a heated debate over abortion rights.
In a surprising address, President Trump challenges vaccine safety and calls for changes to childhood immunization schedules, alarming health experts and political allies alike.
The Trump administration has sparked debate by proposing restrictions on one medication linked to autism, while advocating for broader access to another under investigation. What does this mean for future healthcare decisions?
